Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and CRISPR-associated (Cas) systems, initially discovered as a bacterial defense mechanism against viral infections, have emerged as powerful tools in molecular biology. In recent years, researchers have harnessed CRISPR-Cas systems for precision antimicrobial therapy, offering a targeted approach to combat infectious diseases. CRISPR-Cas systems can be programmed to specifically target and cleave the DNA of pathogenic bacteria, leaving non-pathogenic bacteria and host cells unharmed. This precision is achieved by designing guide RNAs that complement the DNA sequences of the target bacteria. The Cas proteins then act as molecular scissors, cutting the bacterial DNA at the specified locations. This approach allows for the selective elimination of harmful bacteria while minimizing collateral damage to beneficial microbes. Moreover, CRISPR-Cas technology offers the potential to overcome antibiotic resistance. By targeting specific resistance genes, CRISPR-Cas systems can disable the mechanisms that confer resistance, making bacteria susceptible to conventional antibiotics once again. This innovative strategy holds promise for developing personalized and adaptable antimicrobial therapies, tailored to the genomic characteristics of infectious agents. Continued research in this field may pave the way for a new era of precision medicine in the fight against bacterial infections.